TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 2nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 4nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 8nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 9nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 9nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 10nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 10nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 12nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 13nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 18nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 19nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 19nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 20nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 22nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 22nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 23nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 24nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 27nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 27nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)
US Patent
Ascentage Pharma (Suzhou)
US Patent
Affinity DataIC50: 29nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair